1.72
price down icon6.01%   -0.11
after-market アフターアワーズ: 1.72
loading
前日終値:
$1.83
開ける:
$1.8
24時間の取引高:
1.27M
Relative Volume:
0.59
時価総額:
$143.98M
収益:
$32.31M
当期純損益:
$-237.09M
株価収益率:
-0.5972
EPS:
-2.88
ネットキャッシュフロー:
$-219.11M
1週間 パフォーマンス:
+10.97%
1か月 パフォーマンス:
+10.97%
6か月 パフォーマンス:
-23.21%
1年 パフォーマンス:
-66.73%
1日の値動き範囲:
Value
$1.70
$1.81
1週間の範囲:
Value
$1.5646
$1.9499
52週間の値動き範囲:
Value
$0.9101
$6.22

Editas Medicine Inc Stock (EDIT) Company Profile

Name
名前
Editas Medicine Inc
Name
セクター
Healthcare (1170)
Name
電話
617-401-9000
Name
住所
11 HURLEY ST., CAMBRIDGE, MA
Name
職員
226
Name
Twitter
@editasmed
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
EDIT's Discussions on Twitter

EDIT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
EDIT
Editas Medicine Inc
1.72 129.75M 32.31M -237.09M -219.11M -2.88
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-28 開始されました H.C. Wainwright Buy
2024-12-16 ダウングレード JP Morgan Neutral → Underweight
2024-12-13 ダウングレード Chardan Capital Markets Buy → Neutral
2024-12-13 ダウングレード Stifel Buy → Hold
2024-12-13 ダウングレード Truist Buy → Hold
2024-12-11 ダウングレード Wells Fargo Overweight → Equal Weight
2024-11-25 ダウングレード BofA Securities Buy → Underperform
2024-11-06 アップグレード Evercore ISI In-line → Outperform
2024-11-04 ダウングレード Raymond James Outperform → Mkt Perform
2024-08-08 アップグレード BofA Securities Neutral → Buy
2024-05-09 アップグレード Morgan Stanley Underweight → Equal-Weight
2023-10-24 アップグレード Citigroup Neutral → Buy
2023-10-18 アップグレード JP Morgan Underweight → Neutral
2023-10-17 ダウングレード Cantor Fitzgerald Overweight → Neutral
2023-09-29 アップグレード Stifel Hold → Buy
2023-06-12 アップグレード Raymond James Mkt Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2022-12-13 開始されました Citigroup Neutral
2022-12-06 再開されました Credit Suisse Neutral
2022-11-18 ダウングレード Credit Suisse Outperform → Neutral
2022-11-18 ダウングレード Oppenheimer Outperform → Perform
2022-09-29 開始されました BofA Securities Neutral
2021-10-19 開始されました SVB Leerink Mkt Perform
2021-09-24 開始されました Stifel Hold
2021-09-10 アップグレード Oppenheimer Perform → Outperform
2021-08-09 アップグレード Truist Hold → Buy
2021-08-05 アップグレード Evercore ISI Underperform → Outperform
2021-06-04 再開されました Robert W. Baird Outperform
2021-05-04 開始されました RBC Capital Mkts Sector Perform
2021-04-16 開始されました Goldman Sell
2021-03-22 開始されました Credit Suisse Outperform
2021-03-01 ダウングレード Barclays Overweight → Equal Weight
2021-02-26 ダウングレード Truist Buy → Hold
2021-01-19 ダウングレード Morgan Stanley Equal-Weight → Underweight
2021-01-07 ダウングレード Raymond James Outperform → Mkt Perform
2020-12-10 アップグレード Wells Fargo Equal Weight → Overweight
2020-11-03 開始されました Robert W. Baird Underperform
2020-06-18 再開されました SunTrust Buy
2020-02-21 開始されました Wells Fargo Equal Weight
2019-04-12 開始されました Evercore ISI Outperform
2018-10-10 開始されました Guggenheim Neutral
2018-09-21 開始されました Raymond James Outperform
2018-05-15 繰り返されました Chardan Capital Markets Buy
2018-02-13 開始されました CLSA Underperform
2018-01-23 アップグレード SunTrust Hold → Buy
2017-07-14 開始されました SunTrust Hold
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-10 アップグレード Jefferies Hold → Buy
2016-06-02 開始されました Jefferies Hold
2016-02-29 開始されました JMP Securities Mkt Outperform
2016-02-29 開始されました JP Morgan Neutral
2016-02-29 開始されました Morgan Stanley Equal-Weight
すべてを表示

Editas Medicine Inc (EDIT) 最新ニュース

pulisher
May 31, 2025

Millennium Management LLC Cuts Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World

May 31, 2025
pulisher
May 30, 2025

Two Sigma Advisers LP Grows Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 30, 2025
pulisher
May 30, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by BNP Paribas Financial Markets - Defense World

May 30, 2025
pulisher
May 30, 2025

Northern Trust Corp Has $884,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World

May 30, 2025
pulisher
May 28, 2025

Brokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Editas Medicine (EDIT) Joins Russell Microcap Index - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com

May 28, 2025
pulisher
May 26, 2025

Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges By Investing.com - Investing.com Canada

May 26, 2025
pulisher
May 26, 2025

Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges - Investing.com Australia

May 26, 2025
pulisher
May 25, 2025

1 Stock Down 97% That Could Double, According to Wall Street - The Globe and Mail

May 25, 2025
pulisher
May 24, 2025

Tang Capital Management LLC Purchases Shares of 400,000 Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 24, 2025
pulisher
May 23, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Brokerages - Defense World

May 23, 2025
pulisher
May 22, 2025

Jacobs Levy Equity Management Inc. Has $900,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 22, 2025
pulisher
May 21, 2025

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28% - simplywall.st

May 21, 2025
pulisher
May 20, 2025

Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT S - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

May 19, 2025
pulisher
May 19, 2025

Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT Stock News - GuruFocus

May 19, 2025
pulisher
May 18, 2025

Stifel Financial Corp Sells 287,718 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 18, 2025
pulisher
May 18, 2025

Robert W. Baird Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $4.00 - MarketBeat

May 18, 2025
pulisher
May 17, 2025

Balyasny Asset Management L.P. Grows Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 17, 2025
pulisher
May 16, 2025

Crispr Therapeutics Products 2025: Therapies, MOA Insights, - openPR.com

May 16, 2025
pulisher
May 16, 2025

Editas Medicine (NASDAQ:EDIT) Stock Rating Upgraded by StockNews.com - Defense World

May 16, 2025
pulisher
May 15, 2025

Editas Medicine: A Cautionary Tale for Investors - AOL.com

May 15, 2025
pulisher
May 15, 2025

Raymond James Financial Inc. Invests $303,000 in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 15, 2025
pulisher
May 15, 2025

A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory - Pharma Voice

May 15, 2025
pulisher
May 15, 2025

Robert W. Baird Issues Pessimistic Forecast for Editas Medicine (NASDAQ:EDIT) Stock Price - Defense World

May 15, 2025
pulisher
May 14, 2025

Editas Medicine Reports Q1 2025 Progress and Financials - TipRanks

May 14, 2025
pulisher
May 14, 2025

Editas Medicine: A Cautionary Tale For Investors - Barchart.com

May 14, 2025
pulisher
May 14, 2025

Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN

May 14, 2025
pulisher
May 14, 2025

Editas Medicine to Present in vivo HSC Delivery, Editing, and Bi - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Editas Medicine to Present in vivo HSC Delivery, Editing, - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the ... - Bluefield Daily Telegraph

May 14, 2025
pulisher
May 14, 2025

Editas optimistic on CRISPR patent outcome after appeal By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Editas Medicine (EDIT) Advances Gene Editing for Blood Disorders with Promising Results | EDIT Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports New In Vivo Data Highlighting The Potential Of Editas' Gene Upregulation Strategy In Hscs At The American Society Of Gene And Cell Therapy Annual Meeting - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports New In Vivo Data Highlighting the Potent - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Editas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs - TipRanks

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Unveils Promising Gene Editing Data - TipRanks

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports Promising In Vivo Gene Editing Results for Sickle Cell Disease and Beta Thalassemia at ASGCT Annual Meeting - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports New In Vivo Data Highlighting the - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - TradingView

May 14, 2025
pulisher
May 14, 2025

Editas Medicine at BofA Securities 2025: In Vivo Gene Editing Focus - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Dimensional Fund Advisors LP - Defense World

May 14, 2025
pulisher
May 14, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Wells Fargo & Company MN - MarketBeat

May 14, 2025
pulisher
May 14, 2025

Breakthrough: Editas Medicine's New Gene Therapy Data Shows 48% Success Rate for Sickle Cell Disease Treatment - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Editas Medicine Reports New In Vivo Proof of Concept Data - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Transcript : Editas Medicine, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com

May 13, 2025

Editas Medicine Inc (EDIT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
大文字化:     |  ボリューム (24 時間):